We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Status: Unknown

Mar 2nd 2020 - Apr 1st 2020

Sweat IT is a fitness studio in London, which provides supreme high-intensity training experience with the hardest workouts. The UK fitness industry continues to grow high at a value of over £5 billion because of increasing demand for a healthy lifestyle. Sweat IT redefines this with healthy eating and exercise. The company has the vision to take its business growth to the next level and become the leader of boutique fitness. They have partnered with Gympass, the world’s leading corporate fitness platform to deliver high-intensity fitness classes to London based corporate clients. Till date, they have had over 50,000 class bookings with more than 13,000 Instagram followers and a database of 10,000 customers. The company intends on using the investment for marketing and product branding and next-level growth. They are also looking to fund their second studio in London and have ear-marked a potential site in the City.

read more read less

Sweat IT Rating Review

Pitch rating powered by CROWDRATING

Rated on 12/03/2020

Pitch Rated

67%

overall

Management

64%

Product

66%

Investment

70%

Log in to view amount pledged

    Log in to view target

    £3,400,000
    pre-money valuation

    15.00%
    equity available

    74
    investors

    £2,854
    pledge per investor

    10437091
    company number

    Dissolved
    company status

    19/10/2016
    incorporated 8 years

    Previous Funding rounds
    14 Apr 24 Crowdcube £211,220 / 35% 66.67%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 64%

Skills 55%
The CEO and the head trainer both are highly skilled and knowledgeable professionals who are passionate about fitness which leads to the creation of Sweat IT. The head trainer of the company is a professional multi-tasker who has the potential to lead the trainer team at Sweat It London, along with coaching sessions in the studio. The CEO has not previously managed in the health and fitness industry. However, the management team lacks a finance head who would be beneficial for the company at this stage of fundraising.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £3,400,000
    pre-money valuation

    15.00%
    equity available

    74
    investors

    £2,854
    pledge per investor

    10437091
    company number

    Dissolved
    company status

    19/10/2016
    incorporated 8 years

    Previous Funding rounds
    19 Apr 24 Crowdcube £211,220 / 35% 66.67%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph